

February 7, 2007

AnGes MG, Inc.

New Medical-Use Patent for HGF Gene Granted in Japan
- Covering Intractable and Diabetes-related
Peripheral Arterial Occlusive Diseases -

AnGes MG, Inc. announces that a patent for the medical use of HGF gene for diabetes-related ischemic diseases was granted in Japan, and Patent Gazette (Patent No. 3877148) was issued today.

AnGes MG has filed a basic patent application for “HGF plasmid as a medicament for treating arterial diseases for which HGF is effective, comprising intramuscular administration of an expression vector containing an HGF gene” and these corresponding patents have been granted in Japan, the U.S. and Europe.

Ischemic diseases complicated with or caused by diabetes mellitus are known for poorer prognosis because of difficulty in inducing neoangiogenesis. Under these circumstances, AnGes MG separately examined the efficacy of HGF plasmid for intractable and diabetes-related peripheral arterial occlusive diseases and globally filed its patent application.

As a result, the above patent application has been granted in Japan, China and Australia and is currently patent pending in the U.S., Canada, Europe, South Korea and Taiwan.

According to the Ministry of Health, Labour and Welfare’s diabetes mellitus survey, it is estimated that approximately 7.4 million people are strongly suspected of having diabetes mellitus and approximately 16.2 million people are recorded as being affected, including those undoubtedly suspected of being affected by the disease (2002).

This patent will strongly support the development project of HGF gene therapy. While also eyeing its global development, AnGes MG will make efforts to further establish a strong patent network.